Mylan NV operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mylan NV with three other
companies in this sector in UNITED STATES :
Daiichi Sankyo Company Limited
sales of $8.38 billion
of which 93%
was Prescription drugs),
Regeneron Pharmaceuticals Incorporated
of which 59%
was EYLEA), and
of which 84%
was CSL Behring).
Mylan NV reported sales of $11.50 billion
December of 2019.
a very small
increase of 0.6%
versus 2018, when the company's sales were $11.43 billion.
Despite this increase, sales are still
below the level achieved in 2017, when Mylan NV
reported sales of $11.91 billion.
Sales of Rest of World saw an increase
that was more than double the company's growth rate: sales were up
5.5% in 2019, from
$3.04 billion to $3.21 billion.
Not all segments of Mylan NV experienced an increase in sales in 2019:
sales of Europe fell 3.1% to $4.05 billion.